Cytaright 100mg/1ml Injection

• Acute myeloid leukemia (AML)
• Chronic myelogenous leukemia (CML)
• Meningeal leukaemia

The human body shows undesired symptoms after taking Cytaright 100mg/1ml Injection. Usually, they disappear with time as the body adjusts to the medicine. These side effects don't need special medical attention. It is advised to consult your doctor if these symptoms become unmanageable.
Common side effects include:

• Rash
• Skin ulcer
• Nausea
• Vomiting
• Hair loss
• Abdominal pain
• Anal ulcers
• Anemia (low number of red blood cells)
• Decreased white blood cell count
• Fever
• Infection
• Abnormal liver function
• Low blood platelets
• Mouth ulcer
• Pneumonia
• Sepsis
• Mouth sore
• Stomatitis (Inflammation of the mouth)

• Cytaright 100mg/1ml is available in injection form and is advised to be taken as per the doctor's prescription. It can be given under the skin (subcutaneous) into a vein (intravenously) into a muscle (intramuscularly) or the spine (intrathecal) by a doctor or nurse under strict medical supervision.Taking this injection in the wrong way may give you severe side effects.
• In case of overdose, contact your healthcare provider or doctor and they will provide you with medical attention. Missing or overdosing will impact the overall health of the patients and may also have side effects. So, it is always advisable to follow the prescription of the doctor strictly.
  

• Cytaright 100mg/1ml Injection is a cytotoxic drug that contains Cytarabine as an active ingredient. It works by primarily killing cancer cells by interfering with their DNA synthesis.
• It causes the DNA strands to cross-link, that stops the cells from dividing and ultimately leads to their death. Results in slowing or stopping the growth of cancer cells in your body.
  
  

• Chhikara, B. S., & Parang, K. (2010). Development of cytarabine prodrugs and delivery systems for leukemia treatment. Expert opinion on drug delivery, 7(12), 1399-1414. https://pubmed.ncbi.nlm.nih.gov/20964588/
• Magina, K. N., Pregartner, G., Zebisch, A., Wölfler, A., Neumeister, P., Greinix, H. T., ... & Sill, H. (2017). Cytarabine dose in the consolidation treatment of AML: a systematic review and meta-analysis. Blood, the Journal of the American Society of Hematology, 130(7), 946-948. https://pubmed.ncbi.nlm.nih.gov/28679736/
• Löwenberg, B., Pabst, T., Vellenga, E., van Putten, W., Schouten, H. C., Graux, C., ... & Ossenkoppele, G. J. (2011). Cytarabine dose for acute myeloid leukemia. New England Journal of Medicine, 364(11), 1027-1036. https://pubmed.ncbi.nlm.nih.gov/21410371/
• Hamada, A., Kawaguchi, T., & Nakano, M. (2002). Clinical pharmacokinetics of cytarabine formulations. Clinical pharmacokinetics, 41(10), 705-718. https://pubmed.ncbi.nlm.nih.gov/12162758/
• El-Subbagh, H. I., & Al-Badr, A. A. (2009). Cytarabine. In profiles of drug substances, excipients and related methodology (Vol. 34, pp. 37-113). Academic Press.
• Löwenberg, B., Pabst, T., Vellenga, E., van Putten, W., Schouten, H. C., Graux, C., ... & Ossenkoppele, G. J. (2011). Cytarabine dose for acute myeloid leukemia. New England Journal of Medicine, 364(11), 1027-1036. https://cris.maastrichtuniversity.nl/en/publications/cytarabine-dose-for-acute-myeloid-leukemia/